Teachers Retirement System of The State of Kentucky Boosts Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Teachers Retirement System of The State of Kentucky grew its position in Edwards Lifesciences Co. (NYSE:EW) by 43.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 138,755 shares of the medical research company’s stock after acquiring an additional 42,059 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Edwards Lifesciences were worth $9,156,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in EW. Lantz Financial LLC grew its stake in Edwards Lifesciences by 25.3% during the 2nd quarter. Lantz Financial LLC now owns 3,236 shares of the medical research company’s stock valued at $299,000 after acquiring an additional 654 shares in the last quarter. ORG Partners LLC increased its holdings in shares of Edwards Lifesciences by 1,133.0% in the second quarter. ORG Partners LLC now owns 1,159 shares of the medical research company’s stock valued at $105,000 after purchasing an additional 1,065 shares during the last quarter. Valley National Advisers Inc. increased its holdings in shares of Edwards Lifesciences by 40.5% in the second quarter. Valley National Advisers Inc. now owns 3,760 shares of the medical research company’s stock valued at $347,000 after purchasing an additional 1,083 shares during the last quarter. Blue Trust Inc. boosted its stake in Edwards Lifesciences by 38.2% during the second quarter. Blue Trust Inc. now owns 5,051 shares of the medical research company’s stock worth $483,000 after buying an additional 1,397 shares during the last quarter. Finally, Oak Harbor Wealth Partners LLC grew its holdings in Edwards Lifesciences by 4.8% in the 2nd quarter. Oak Harbor Wealth Partners LLC now owns 7,514 shares of the medical research company’s stock valued at $694,000 after buying an additional 341 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Robert W. Baird lowered their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. The Goldman Sachs Group boosted their target price on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, December 5th. Citigroup increased their price target on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research note on Wednesday. UBS Group reduced their price target on shares of Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating on the stock in a research report on Tuesday, September 10th. Finally, Piper Sandler lowered their price objective on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Seventeen equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Hold” and an average target price of $78.65.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the transaction, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 35,000 shares of company stock worth $2,323,150. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $73.97 on Friday. The firm has a 50 day moving average of $69.09 and a two-hundred day moving average of $74.19. The stock has a market capitalization of $43.63 billion, a PE ratio of 10.67, a P/E/G ratio of 3.52 and a beta of 1.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.67. The firm had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Edwards Lifesciences’s revenue was up 8.9% compared to the same quarter last year. During the same period last year, the business posted $0.59 earnings per share. On average, research analysts predict that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.